← Back to Search

Unknown

AGN-241622 for Presbyopia

Phase 1 & 2
Waitlist Available
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights

Study Summary

This trial is testing a new eye drop to see if it is safe and effective in humans.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Stage 1: Number of Participants Experiencing a Treatment Emergent Adverse Event After Single Administration of AGN-241622
Stage 2a: Number of Patients Experiencing a Treatment Emergent Adverse Event After Repeat Administration of AGN-241622
Secondary outcome measures
Stage 1 Plasma Pharmacokinetics: Apparent Total Clearance of AGN-241622 From Plasma (CL/F)
Stage 1 Plasma Pharmacokinetics: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of AGN-241622
Stage 1 Plasma Pharmacokinetics: Area Under the Concentration-time Curve From Time 0 to Time t (AUC0-t) of AGN-241622
+28 more

Trial Design

7Treatment groups
Experimental Treatment
Placebo Group
Group I: Cohort 6: AGN-241622 Dose 3 (High Dose)Experimental Treatment1 Intervention
Administered as single drop in each eye
Group II: Cohort 5: AGN-241622 Dose 2 (Medium Dose)Experimental Treatment1 Intervention
Administered as single drop in each eye
Group III: Cohort 4: AGN-241622 Dose 1 (Low Dose)Experimental Treatment1 Intervention
Administered as a single drop in each eye
Group IV: Cohort 3: AGN-241622 Dose 3 (High Dose)Experimental Treatment1 Intervention
Administered as single drop in one eye
Group V: Cohort 2: AGN-241622 Dose 2 (Medium Dose)Experimental Treatment1 Intervention
Administered as single drop in one eye
Group VI: Cohort 1: AGN-241622 Dose 1 (Low Dose)Experimental Treatment1 Intervention
Administered as single drop in one eye
Group VII: Placebo DosePlacebo Group1 Intervention
Administered as single drop in one or both eyes

Find a Location

Who is running the clinical trial?

AllerganLead Sponsor
781 Previous Clinical Trials
276,489 Total Patients Enrolled
8 Trials studying Presbyopia
1,402 Patients Enrolled for Presbyopia
AbbVieLead Sponsor
954 Previous Clinical Trials
500,964 Total Patients Enrolled
1 Trials studying Presbyopia
Wayne Chen, PharmDStudy DirectorAllergan

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to partake in this research project?

"This clinical trial has established criteria for inclusion, requiring that applicants have presbyopia and be aged between 40-65. A total of 144 participants are sought after to complete the study."

Answered by AI

How many areas within the state are currently conducting this research?

"This research project is currently enrolling participants from 15 different centres, including Total Eye Care PA /ID# 234454 in Memphis, PPD Development LP in Austin, and Clinical Research Center FL /ID# 237330in Pompano Beach."

Answered by AI

What aims does this research endeavor seek to attain?

"This trial, which is estimated to last up to 2 days, will be examining the number of patients that experience adverse effects following repeated administration of AGN-241622. Secondary outcomes include assessing systemic and local pharmacokinetics in healthy individuals with a single unilateral dose; determining time of maximum plasma concentration after repeat bilateral doses in presbyopia participants; as well as measuring tear concentrations over an extended period for those given one unilateral dose."

Answered by AI

Are there still open slots for enrollment in this clinical experiment?

"Data hosted on clinicaltrials.gov indicates that this medical study, which was first listed on July 27th 2020, is actively recruiting."

Answered by AI

How many participants are involved in this clinical trial thus far?

"Affirmative. According to clinialtrials.gov, this experiment is presently seeking volunteers - it was originally published on July 27th 2020 and its most recent updates were made November 11th 2022. A total of 144 patients are needed across 15 sites."

Answered by AI

Does this clinical experiment accept individuals aged over twenty?

"Based on the qualifications for participation, enrollees must be between 40 and 65 years of age."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia
2020. "Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04403763.
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top